MoonLake Immunotherapeutics is pioneering the use of Nanobody® technology to develop innovative therapies for serious inflammatory diseases. Their lead investigational product, Sonelokimab, is a humanized Nanobody® designed to target and inhibit the interleukins IL-17A and IL-17F, which are key drivers of various inflammatory conditions such as psoriasis, hidradenitis suppurativa, psoriatic arthritis, and ankylosing spondylitis. The unique structure of Sonelokimab, which consists of three variable heavy-chain domains, allows for enhanced tissue penetration and the ability to effectively reach difficult-to-access inflamed tissues. This targeted approach aims to improve patient outcomes by directly addressing the underlying inflammatory processes.

The advantages of Nanobody® technology over traditional antibodies include their smaller size, which facilitates better tissue distribution, and their stability under varying conditions, making them easier to manufacture. Sonelokimab's design not only enhances its binding affinity to IL-17 dimers but also incorporates a domain that binds to human albumin, further increasing its concentration at sites of inflammation. This innovative therapeutic strategy represents a significant advancement in the treatment of inflammatory diseases, addressing critical unmet medical needs and potentially transforming the clinical landscape for affected patients.

Switzerland

MoonLake has a portfolio of therapeutic programs based on the phase 3-ready Nanobody® Sonelokimab (SLK, M1095/ALX-0761), a biologic molecule potentially capable of driving disease modification in dermatology and rheumatology patients. A single-domain antibody (sdAb), also known as a Nanobody®, is an antibody fragment consisting of a single monomeric variable antibody domain. Like antibodies, Nanobodies® are able to bind selectively to a specific antigen with high affinity.

MoonLake Immunotherapeutics

Company Details